COVID-19 Vaccine Response in People with Multiple Sclerosis.
COVID-19 Vaccine Response in People with Multiple Sclerosis.
复制标题
DOI：
10.1002/ana.26251
复制
发表时间：
2022-01
影响因子：
11.2
通讯作者：
Dobson R
中科院分区：
文献类型：
--
作者：
Tallantyre EC;Vickaryous N;Anderson V;Asardag AN;Baker D;Bestwick J;Bramhall K;Chance R;Evangelou N;George K;Giovannoni G;Godkin A;Grant L;Harding KE;Hibbert A;Ingram G;Jones M;Kang AS;Loveless S;Moat SJ;Robertson NP;Schmierer K;Scurr MJ;Shah SN;Simmons J;Upcott M;Willis M;Jolles S;Dobson R
本研究的目的是研究疾病修饰疗法对多发性硬化症（MS）患者对严重急性呼吸综合征-冠状病毒2（SARS-CoV-2）疫苗免疫应答的影响。473名MS患者提供了一个或多个干血斑样本。有关2019年冠状病毒病（COVID-19）以及疫苗史、病史和药物史的信息摘自问卷和病历。洗脱干血点并检测SARS-CoV-2抗体。抗体滴度被分成三分位数，没有接受疾病修饰治疗的人作为参考。我们计算了血清转换的比值比（单变量logistic回归），并根据疾病修饰治疗比较了SARS-CoV-2疫苗接种后的定量疫苗应答（Kruskal沃利斯）。我们使用回归模型来探讨疫苗接种时间、治疗持续时间、年龄、疫苗类型和淋巴细胞计数对疫苗应答的影响。与无疾病修饰治疗相比，使用抗CD 20单克隆抗体（比值比= 0.03，95%置信区间[CI] = 0.01-0.06，p < 0.001）和芬戈莫德（比值比= 0.04; 95% CI = 0.01-0.12）与SARS-CoV-2疫苗后较低的血清转换相关。所有其他药物与未经治疗的队列无显著差异。自末次抗CD 20治疗后的时间和治疗总时间均与疫苗接种应答显著相关。疫苗类型可显著预测血清转换，但在抗CD 20药物治疗的患者中并非如此。细胞T细胞免疫的初步数据显示，40%的血清阴性受试者具有可测量的抗SARS-CoV-2 T细胞应答。一些疾病修饰疗法传达了MS患者对SARS-CoV-2疫苗接种的血清学反应减弱的风险。我们为这一患者群体的实际管理提供了建议。神经网络20219999：不适用-不适用
The purpose of this study was to investigate the effect of disease modifying therapies on immune response to severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) vaccines in people with multiple sclerosis (MS). Four hundred seventy‐three people with MS provided one or more dried blood spot samples. Information about coronavirus disease 2019 (COVID‐19) and vaccine history, medical, and drug history were extracted from questionnaires and medical records. Dried blood spots were eluted and tested for antibodies to SARS‐CoV‐2. Antibody titers were partitioned into tertiles with people on no disease modifying therapy as a reference. We calculated the odds ratio of seroconversion (univariate logistic regression) and compared quantitative vaccine response (Kruskal Wallis) following the SARS‐CoV‐2 vaccine according to disease modifying therapy. We used regression modeling to explore the effect of vaccine timing, treatment duration, age, vaccine type, and lymphocyte count on vaccine response. Compared to no disease modifying therapy, the use of anti‐CD20 monoclonal antibodies (odds ratio = 0.03, 95% confidence interval [CI] = 0.01–0.06, p < 0.001) and fingolimod (odds ratio = 0.04; 95% CI = 0.01–0.12) were associated with lower seroconversion following the SARS‐CoV‐2 vaccine. All other drugs did not differ significantly from the untreated cohort. Both time since last anti‐CD20 treatment and total time on treatment were significantly associated with the response to the vaccination. The vaccine type significantly predicted seroconversion, but not in those on anti‐CD20 medications. Preliminary data on cellular T‐cell immunity showed 40% of seronegative subjects had measurable anti‐SARS‐CoV‐2 T cell responses. Some disease modifying therapies convey risk of attenuated serological response to SARS‐CoV‐2 vaccination in people with MS. We provide recommendations for the practical management of this patient group. ANN NEUROL 20219999:n/a–n/a
登录
查看更多内容
影响因子：
16.6
作者：
Roxhed N;Bendes A;Dale M;Mattsson C;Hanke L;Dodig-Crnković T;Christian M;Meineke B;Elsässer S;Andréll J;Havervall S;Thålin C;Eklund C;Dillner J;Beck O;Thomas CE;McInerney G;Hong MG;Murrell B;Fredolini C;Schwenk JM
通讯作者：
Schwenk JM
影响因子：
5.9
作者：
Achiron A;Mandel M;Dreyer-Alster S;Harari G;Magalashvili D;Sonis P;Dolev M;Menascu S;Flechter S;Falb R;Gurevich M
通讯作者：
Gurevich M
影响因子：
5.3
作者：
Sormani MP;Salvetti M;Labauge P;Schiavetti I;Zephir H;Carmisciano L;Bensa C;De Rossi N;Pelletier J;Cordioli C;Vukusic S;Moiola L;Kerschen P;Radaelli M;Théaudin M;Immovilli P;Casez O;Capobianco M;Ciron J;Trojano M;Stankoff B;Créange A;Tedeschi G;Clavelou P;Comi G;Thouvenot E;Battaglia MA;Moreau T;Patti F;De Sèze J;Louapre C;Musc-19;Covisep study groups
通讯作者：
Covisep study groups
影响因子：
2.2
作者：
Moat SJ;Zelek WM;Carne E;Ponsford MJ;Bramhall K;Jones S;El-Shanawany T;Wise MP;Thomas A;George C;Fegan C;Steven R;Webb R;Weeks I;Morgan BP;Jolles S
通讯作者：
Jolles S
影响因子：
64.5
作者：
Moderbacher, Carolyn Rydyznski;Ramirez, Sydney, I;Crotty, Shane
通讯作者：
Crotty, Shane